

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listing of claims in the application:

**Listing of claims:**

1 (currently amended). A stable, liquid formulation comprising (a) an anti-IgE antibody that is rhuMAbE25 in an amount of 120 to 260 mg/ml, (b) arginine-HCl in an amount of 50100 to 200 mM, (c) histidine in an amount of 10 to 100 mM, (d) polysorbate in an amount of 0.01 to 0.1%, where the formulation further has a pH ranging from 5.5 to 7.0, a kinematic viscosity of about 50 cs or less, an osmolarity ranging from 200 mOsm/kg to 450 mOsm/kg and a turbidity of 0.30 O.D. or less mean absorbance as measured by a 1-cm quartz cuvette using an Hewlett-Packard 8453 diode array spectrophotometer ~~or equivalent~~ at 340-360 nm.

2 (Canceled).

3 (Previously presented). The formulation of Claim 1, wherein the concentration of antibody ranges from 150 mg/ml to 260 mg/ml.

4 (Previously presented). The formulation of Claim 1, wherein the concentration of antibody ranges from 180 mg/ml to 260 mg/ml.

5 (Previously presented). The formulation of Claim 1, wherein the concentration of antibody ranges from 200 mg/ml to 260 mg/ml.

6 (Previously presented). The formulation of Claim 1, wherein the concentration of antibody is about 150 mg/ml.

7 (original). The formulation of Claim 1, wherein the osmolarity ranges from 250 mOsm/kg to 350 mOsm/kg.

8 (Currently amended). The formulation of Claim 1, wherein the concentration of arginine-HCl ~~ranges from 100 mM to~~ is 200 mM.

9 - 19 (Canceled).

20 (Currently amended). A stable, liquid formulation comprising (a) an anti-IgE antibody that is rhUMAbE25 in an amount of about 150 mg/ml, (b) arginine-HCl in an amount of 200 mM, (c) histidine in an amount of 20 mM, (d) polysorbate in an amount of 0.02%, where the formulation further has a pH of 6.0 and a turbidity of 0.30 O.D. or less mean absorbance as measured by a 1-cm quartz cuvette using an Hewlett-Packard 8453 diode array spectrophotometer at 340-360 nm.

21 (canceled).

22 (Currently amended). An article of manufacture comprising a container enclosing the formulation of Claims 1 or 20.

23 (original). The article of manufacture of Claim 22, wherein the container is a syringe.

24 (original). The article of manufacture of Claim 23, wherein the syringe is further contained within an injection device.

25 (original). The article of manufacture of Claim 24, wherein the injection device is an auto-injector.

26 - 50 (canceled).